Scribd
Upload
105 views

Platelet

Platelets are cell fragments involved in hemostasis and forming blood clots. They are produced in bone marrow and have a lifespan of 5-9 days. Abnormalities of platelets can cause issues with clotting and bleeding. Thrombocytopenia is a low platelet count which increases bleeding risk, while thrombocytosis is a high platelet count which can increase thrombosis risk. Many disorders can affect platelet number or function.

Uploaded by

Fafha Fafha
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
105 views

Platelet

Platelets are cell fragments involved in hemostasis and forming blood clots. They are produced in bone marrow and have a lifespan of 5-9 days. Abnormalities of platelets can cause issues with clotting and bleeding. Thrombocytopenia is a low platelet count which increases bleeding risk, while thrombocytosis is a high platelet count which can increase thrombosis risk. Many disorders can affect platelet number or function.

Uploaded by

Fafha Fafha
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
You are on page 1/ 15

Muhammad Nazarudin, S.

ST
 Platelets, or thrombocytes (from Greek
θρόμβος, "clot" and κύτος, "cell")
 small, irregularly shaped clear cell fragments
 2–3 µm in diameter
 derived from fragmentation of precursor
megakaryocytes
 lifespan of a platelet is normally just in avg 5
to 9 days
 involvedin hemostasis, leading to the
formation of blood clots
 Pro-coagulation
 Inflammation
 Cytokine signalling
 Phagocytosis
 An abnormality or disease of the platelets is
called a thrombocytopathy, which could be
either a low number of platelets
(thrombocytopenia), a decrease in function
of platelets (thrombasthenia), or an increase
in the number of platelets (thrombocytosis).
 There are disorders that reduce the number
of platelets, such as heparin-induced
thrombocytopenia (HIT) or thrombotic
thrombocytopenic purpura (TTP) that
typically cause thromboses, or clots, instead
of bleeding.
 Platelets are produced in blood cell
formation (thrombopoiesis) in bone marrow,
by budding off from megakaryocytes.
 The physiological range for platelets is (150–
400)×109per liter.
 Around 1011 platelets are produced each day
by an average healthy adult.
 The lifespan of circulating platelets is 5 to 9
days.
 Megakaryocyte and platelet production is
regulated by thrombopoietin, a hormone
usually produced by the liver and kidneys.
 Each megakaryocyte produces between 5,000
and 10,000 platelets.
 Old platelets are destroyed
by phagocytosis in thespleen and by Kupffer
cells in the liver.
 Reserve platelets are stored in the spleen,
and are released when needed by
sympathetically induced splenic contraction.
 Role
 A normal platelet count in a healthy individual is
between 150,000 and 450,000 per μl (microlitre) of
blood ((150–450)×109/L)
 Both thrombocytopenia and thrombocytosis may
present with coagulation problems. In general,
low platelet counts increase bleeding risks;
however there are exceptions (such as immune-
mediated heparin-induced
thrombocytopenia or paroxysmal nocturnal
hemoglobinuria). High counts may lead
to thrombosis, although this is mainly when the
elevated count is due to myeloproliferative
disorder.
 Disorders leading to a reduced platelet
count:
 Thrombocytopenia
 Idiopathic thrombocytopenic purpura – also known as
immune thrombocytopenic purpura (ITP)
 Thrombotic thrombocytopenic purpura
 Drug-induced thrombocytopenic purpura (for
example heparin-induced thrombocytopenia (HIT))
 Gaucher's disease
 Aplastic anemia
 Onyalai
 Alloimmune disorders
 Fetomaternal alloimmune thrombocytopenia
 Some transfusion reactions
 Disorders
leading to platelet dysfunction or
reduced count:
 HELLP syndrome
 Hemolytic-uremic syndrome
 Chemotherapy
 Dengue
 Disorders featuring an elevated count:
 Thrombocytosis, including essential
thrombocytosis (elevated counts, either reactive
or as an expression of myeloproliferative
disease); may feature dysfunctional platelets
 Disorders
of platelet adhesion or
aggregation:
 Bernard-Soulier syndrome
 Glanzmann's thrombasthenia
 Scott's syndrome
 von Willebrand disease
 Hermansky-Pudlak Syndrome
 Gray platelet syndrome
 Disorders of platelet metabolism
 Decreased cyclooxygenase activity, induced or
congenital
 Storage pool defects, acquired or congenital
 Disorders that indirectly compromise platelet
function:
 Haemophilia
 Wiskott–Aldrich syndrome
 Disorders in which platelets play a key role:
 Atherosclerosis
 Coronary artery disease, CAD and myocardial
infarction, MI
 Cerebrovascular disease and Stroke, CVA
(cerebrovascular accident)
 Peripheral artery occlusive disease (PAOD)
 Cancer
 Malaria

You might also like